



Cardiometabolic Benefit Beyond Glycemic Control for T2D: Dual Agonism Duel

Live CE Dinner Symposium | Saturday, June 4, 2022 | 6:15 PM - 9:15 PM

Hilton New Orleans Riverside | St. Charles Ballroom- 3rd floor | Two Poydras Street | New Orleans, LA 70130



82ND SCIENTIFIC SESSIONS
HYBRID | NEW ORLEANS | JUNE 3-7, 2022

...to be held in conjunction with the American Diabetes Association's 82nd Scientific Sessions

DESCRIPTION

The data are in! Unimolecular multiagonists have demonstrated efficacy by concurrent activation of hormone receptors that affect energy homeostasis. During this dinner symposium, learn how emerging agents offer robust glucose control, with a low risk of hypoglycemia, as well as weight loss. Afterwards, engage with faculty over coffee and dessert.

TARGET AUDIENCE

This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows, nurse practitioners, and physician assistants engaged in the care of patients with T2D in the US.

EDUCATIONAL OBJECTIVES

After completing this CE activity, the participant should be better able to:

- Plan strategies to address unmet needs, including treatment initiation and escalation, for diverse patient populations with T2D
- Assess the clinical implications of emerging evidence regarding the incretin effect and the roles of GLP-1 and GIP
- Relate the pathophysiology of GLP-1 and GIP to potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Evaluate and interpret the implications of efficacy and safety data of novel dual agonists for T2D
- Assess preliminary clinical data for novel dual/triple agonists in early phase development and their potential benefits and risks

AGENDA

- Welcome and introductions
- Addressing unmet needs in T2D
- Delineating the incretin effect and the roles of GLP-1 and GIP
- Potential benefits of agonism of multiple receptors that affect energy homeostasis
- Q&A
- Clinical implications of tirzepatide efficacy and safety data
- Previews of coming attractions
- Recap of key points
- Q&A
- ENGAGE60: coffee, dessert, and networking with faculty (60 min)

ACCREDITATION, SUPPORT AND CREDIT



In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AAPA CREDIT DESIGNATION STATEMENT

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



INTERPROFESSIONAL CONTINUING EDUCATION (IPCE) STATEMENT

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

SUPPORT STATEMENT

This activity is supported by an educational grant from Lilly.

DISCLOSURE & CONFLICT OF INTEREST POLICY

Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

FACULTY DISCLOSURES

Planner/Presenter

Juan Pablo Frias, MD

Medical Director and Principal Investigator

Velocity Clinical Research

Los Angeles, CA

Juan Pablo Frias, MD, has a financial interest/relationship or affiliation in the form of:

Advisory Board/Consultant for Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi.

Research Grant from Altimmune, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi.

Speakers' Bureau with Lilly, Merck, and Sanofi.

Planner/Presenter

Donna Ryan, MD

Professor Emerita

Pennington Biomedical

Baton Rouge, LA

Donna Ryan, MD, has a financial interest/relationship or affiliation in the form of:

Advisory Board/Consultant for Altimmune, Amgen, Calibrate, Epitomee, Gila, Lilly, Novo Nordisk, Roman, Scientific Intake, Wondr Health, Xeno Bioscience, YSOPIA, and Zealand.

Speakers' Bureau with Novo Nordisk.

Other: Stock Options with Calibrate, Epitomee, Roman, and Scientific Intake. On Data Safety Monitoring Board for Rhythm.

Co-chair of steering committee for the SELECT Trial for Novo Nordisk.

Presenter

Michael A. Nauck, MD

Professor and Head of Clinical Research

Diabetes Division, St. Josef Hospital

Ruhr University

Bochum, Germany

Michael A. Nauck, MD, has a financial interest/relationship or affiliation in the form of:

Advisory Board/Consultant for Boehringer Ingelheim, Gasherbrum, Inventiva, Lilly, Merck Sharp & Dohme Corp., Novo Nordisk, Pfizer, Sanofi, and Servier.

The following relationships have ended within the last 24 months: Advisory Board/Consultant for AstraZeneca, Berlin-Chemie, and Regor Therapeutics.

All of the relevant financial relationships of individuals for this activity have been mitigated.

PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

REQUIREMENTS FOR SUCCESSFUL COMPLETION

In order to receive credit, learners must participate in the entire CE activity, complete and submit an activity evaluation form using one of the following and your certificate of credit will be generated.

1. Complete the evaluation online available post-activity
2. Complete the evaluation form included in your packet and return to MLI on-site staff or fax to 609.333.1694
3. Scan the QR code



ABOUT THIS ACTIVITY

Medical Learning Institute, Inc. is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Marissa Grossman prior to the live event at mgrossman@mlieducation.org.